Table 3.

Univariate and multiple Cox regression models of GLUT9 polymorphism for explaining the incidence rate of renal events

Variable (Unit of Increase)Fully Adjusted Analysis
CrudeStandard ModelBootstrapping Validated Model
HR (95% CI)P ValueHR (95% CI)P ValueHR (95% CI)P Value
GLUT9 polymorphisma2.35 (1.25 to 4.42)0.0082.17 (1.14 to 4.11)0.022.17 (1.24 to 5.29)0.02
Age (yr)1.00 (0.98 to 1.01)0.661.00 (0.98 to 1.01)0.70
Men1.04 (0.74 to 1.48)0.811.04 (0.71 to 1.51)0.81
Smokingb1.23 (0.90 to 1.68)0.191.23 (0.93 to 1.74)0.21
Diabetesb0.95 (0.69 to 1.30)0.730.95 (0.67 to 1.33)0.74
Cholesterol (1 g/dl)1.00 (0.99 to 1.01)0.591.00 (0.99 to 1.01)0.59
Systolic BP (5 mmHg)1.04 (1.01 to 1.07)0.041.04 (0.99 to 1.08)0.07
Antihypertensive treatmentb1.34 (0.49 to 3.64)0.571.34 (0.52 to 6.12)0.59
Body mass index (1 kg/m2)0.99 (0.96 to 1.02)0.370.99 (0.95 to 1.02)0.35
Hemoglobin (1 g/dl)0.93 (0.85 to 1.02)0.100.93 (0.84 to 1.02)0.12
Albumin (1 g/dl)0.65 (0.48 to 0.90)0.010.65 (0.43 to 0.89)0.02
Phosphate (1 mg/dl)1.12 (0.94 to 1.33)0.221.12 (0.91 to 1.38)0.31
C-reactive protein (1 mg/L)0.99 (0.98 to 1.00)0.180.99 (0.97 to 1.00)0.14
Uric acid (1 g/dl)0.96 (0.89 to 1.03)0.210.96 (0.89 to 1.03)0.24
Urinary protein (1 g/24 h)1.22 (1.14 to 1.31)<0.0011.22 (1.13 to 1.40)0.001
Treatment with allopurinolb0.98 (0.75 to 1.28)0.880.98 (0.74 to 1.31)0.89
eGFRMDRD186 (1 ml/min per 1.73 m2)0.96 (0.95 to 0.97)<0.0010.96 (0.94 to 0.97)0.001
  • Data are expressed as the HR (95% confidence intervals) and P values. The bootstrapping validated 95% CIs are also given (see the Materials and Methods for more details about bootstrapping validation). 95% CI, 95% confidence interval; HR, hazard ratio.

  • a 0=GG; 1=GT+TT.

  • b 0=no; 1=yes.